


Figure 1 - ¹H-NMR spectrum (400 MHz) of the compound of Example 1:


Figure 2 - ^{13}C -NMR spectrum (100 MHz) of the compound of Example 1:


Figure 4 – ¹H-NMR spectrum (400 MHz) of the compound of Example 2 a):



Figure 5 – ^{13}C -NMR spectrum (100 MHz) of the compound of Example 2 a):

Figure 6 – HPLC of the compound obtained in Example 3:

Purity (HPLC):

2.96 %



6/23

HPLC-Column:

Chromolith Performance RP 18e 100-4.6 / linear gradient - Flow 6 ml/min
detection at 220 nm

HPLC-Buffer:

A: 0.1% TFA in water - B: 0.1% TFA in CH₃CN

HPLC-Gradient:

0 % B to 100 % B in 5 min




Figure 7 - ¹H-NMR spectrum (400 MHz) of the compound obtained in Example 4:

Figure 8 - ^{13}C -NMR spectrum (100 MHz) of the compound obtained in Example 4:

9/23

Figure 9 – ¹H-NMR spectrum (400 MHz) of the compound obtained in Example 4a):




Current Data Parameters
NAME: GFT08126-7120942
EXPNO: 1
PROCNO: 1

F2 - Acquisition Parameters
Date_: 20070727
Time: 10.06
INSTRUM: spect
PROBHD: 5 mm PABBO BB-
PULPROG: zg30
TD: 65536
SOLVENT: H2O
NS: 2
DS: 4
SWH: 9223.685 Hz
FIDRES: 0.123483 Hz
AQ: 3.9846387 sec
RG: 456
CW: 60.800 usec
DE: 6.000 usec
TE: 294.2 K
D1: 2.0000000 sec
TD0: 1

===== CHANNEL f1 =====
NUC1: 1H
P1: 13.00 usec
PL1: -1.00 dB
SFO1: 400.1524711 MHz

F2 - Processing parameters
SI: 65536
SF: 400.1500000 MHz
WDR: EM
SSB: 0
LB: 0.30 Hz
GB: 0
PC: 1.40

Figure 10 - ^{13}C -NMR spectrum (100 MHz) of the compound obtained in Example 4a):

Current Data Parameters
 NAME GF708328-7120954
 EXPNO 2
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20070727
 Time 10.08
 INSTRUM spect
 PROBHD 5 mm PABBO BB-
 PULPROG zgpg30
 TD 65536
 SOLVENT DMSO
 NS 512
 DS 4
 SWH 24038.461 Hz
 FIDRES 0.366798 Hz
 AQ 1.3631985 sec
 RG 256
 DM 20.800 usec
 DE 6.00 usec
 TE 295.3 K
 D1 2.0000000 sec
 d11 0.0300000 sec
 DELTA 1.8999998 sec
 TDO 1

===== CHANNEL f1 =====
 NUC1 ^{13}C
 P1 11.00 usec
 PL1 0.00 dB
 SFO1 100.627893 MHz


===== CHANNEL f2 =====
 NUC2 ^1H
 P2 19.00 usec
 PL2 14.78 dB
 SFO2 400.1516006 MHz

===== Processing parameters =====
 SI 32768
 SF 100.617980 MHz
 NDM 0
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40

Figure 11: HPLC of the compound of Example 5:

Purity (HPLC):

≥ 95%



11/23

HPLC-Column: Chromolith Performance RP 18e 100-4,6 / linear gradient - flow 6 ml/min
detection at 220 nm


HPLC-Buffer: A: 0.1% TFA in water - B: 0.1% TFA in CH₃CN
HPLC-Gradient: 0 % B to 100 % B in 5 min

Figure 12 - HPLC of the compound of Example 6:

Purity (HPLC):

> 96 %

12/23



HPLC-Column: Chromolith Performance RP 18e 100-4,6 / linear gradient - flow 6 ml/min
detection at 220 nm

HPLC-Buffer: A: 0.1% TFA in water - B: 0.1% TFA in CH₃CN
HPLC-Gradient: 0 % B to 100 % B in 5 min


Figure 13 - ¹H-NMR spectrum (400 MHz) of the compound of Example 7


Figure 14 - ^{13}C -NMR spectrum (100 MHz) of the compound of Example 7:


Figure 15 - ¹H-NMR spectrum of the compound obtained in Example 8:


Figure 16 - ^{13}C -NMR spectrum of the compound obtained in Example 8:


Figure 17 - ¹H-NMR spectrum of the compound obtained in Example 9:


Figure 18 – ^{13}C -NMR spectrum of the compound obtained in Example 9:



Figure 19 – ¹H-NMR spectrum of the compound of preparation 2:

Figure 20: Tumour remission in breast tumours (MAXF 401) in a comparison of the sodium salt and the corresponding TRIS salt of the compound of Example 4






Figure 21: Selectivity of the anti-tumour activity of the compound of Example 2a in different tumours:

Figure 22: Dose dependency of the anti-tumour action of the compound of Example 2a in breast tumours (MAXF 401 xenograft in nude mice):




Figure 23: Anti-tumour action of the compound of Example 2a in a colon carcinoma xenograft model.

